Literature DB >> 20451961

The "normal" factor VIII concentration in plasma.

Saulius Butenas1, Behnaz Parhami-Seren, Anetta Undas, David N Fass, Kenneth G Mann.   

Abstract

INTRODUCTION: The quantitation of factor (F)VIII by activity-based assays is influenced by the method, procedure, the quality and properties of reagents used and concentrations of other plasma proteins, including von Willebrand factor (VWF).
OBJECTIVE: To compare FVIII concentrations measured by activity-based assays with those obtained by an immunoassay and to establish the influence of plasma dilution on the FVIII clotting activity (FVIIIc).
METHODS: The APTT, a chromogenic assay (Coatest) and two in-house immunoassays were used. Albumin-free recombinant FVIII was used as the calibrator in all assays.
RESULTS: For a group of 44 healthy individuals (HI), the mean value observed for FVIII antigen (FVIIIag; 1.22+/-0.56 nM; S.D.) is substantially higher than that for FVIIIc (0.65+/-0.29 nM) and the chromogenic assay (FVIIIch; 0.50+/-0.23 nM). A positive correlation between FVIIIag and VWFag with R(2)=0.20 was observed. Since plasma VWF has an inhibitory effect on FVIIIc, we evaluated the influence of plasma dilutions on FVIIIc in HI (n=105). At a 4-fold dilution, estimates of FVIIIc by clotting assay were much lower than FVIIIag (0.77+/-0.31 vs. 1.14+/-0.48 nM). At 10- and 25-fold dilutions, the estimated FVIIIc increased to 0.87+/-0.36 and 0.94+/-0.44 nM, respectively.
CONCLUSIONS: 1) In plasma, FVIIIag is higher than FVIIIc and FVIIIch; and 2) Real FVIII concentrations in plasma can be estimated by measuring FVIIIag. (c) 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20451961      PMCID: PMC2910827          DOI: 10.1016/j.thromres.2010.04.004

Source DB:  PubMed          Journal:  Thromb Res        ISSN: 0049-3848            Impact factor:   3.944


  27 in total

Review 1.  Issues with the assay of factor VIII activity in plasma and factor VIII concentrates.

Authors:  R L Lundblad; H S Kingdon; K G Mann; G C White
Journal:  Thromb Haemost       Date:  2000-12       Impact factor: 5.249

2.  Functional effects of the ABO locus polymorphism on plasma levels of von Willebrand factor, factor VIII, and activated partial thromboplastin time.

Authors:  J C Souto; L Almasy; E Muñiz-Diaz; J M Soria; M Borrell; L Bayén; J Mateo; P Madoz; W Stone; J Blangero; J Fontcuberta
Journal:  Arterioscler Thromb Vasc Biol       Date:  2000-08       Impact factor: 8.311

3.  In vitro kinetics of factor VIII activity in patients with mild haemophilia A and a discrepancy between one-stage and two-stage factor VIII assay results.

Authors:  Susan E Rodgers; Elizabeth M Duncan; Denise M Barbulescu; Diana M Quinn; John V Lloyd
Journal:  Br J Haematol       Date:  2007-01       Impact factor: 6.998

4.  Factor VIII and factor VIIIa.

Authors:  P Lollar; P J Fay; D N Fass
Journal:  Methods Enzymol       Date:  1993       Impact factor: 1.600

5.  Elevation of FVIII: C in venous thromboembolism is persistent and independent of the acute phase response.

Authors:  J O'Donnell; A D Mumford; R A Manning; M Laffan
Journal:  Thromb Haemost       Date:  2000-01       Impact factor: 5.249

6.  Intersubunit fluorescence energy transfer in human factor VIII.

Authors:  P J Fay; T M Smudzin
Journal:  J Biol Chem       Date:  1989-08-25       Impact factor: 5.157

7.  Quantitation of anti-factor VIII antibodies in human plasma.

Authors:  Jolanta Krudysz-Amblo; Behnaz Parhami-Seren; Saulius Butenas; Kathleen E Brummel-Ziedins; Edward D Gomperts; Georges E Rivard; Kenneth G Mann
Journal:  Blood       Date:  2009-01-14       Impact factor: 22.113

8.  The influence of von Willebrand factor on factor VIII activity measurements.

Authors:  S Butenas; B Parhami-Seren; K G Mann
Journal:  J Thromb Haemost       Date:  2008-10-29       Impact factor: 5.824

9.  Potency and mass of factor VIII in FVIII products.

Authors:  S Butenas; B Parhami-Seren; M T Gissel; E D Gomperts; D N Fass; K G Mann
Journal:  Haemophilia       Date:  2008-08-06       Impact factor: 4.287

10.  A monoclonal antibody to factor VIII inhibits von Willebrand factor binding and thrombin cleavage.

Authors:  J W Precup; B C Kline; D N Fass
Journal:  Blood       Date:  1991-05-01       Impact factor: 22.113

View more
  5 in total

1.  CD4 T cells specific for factor VIII are present at high frequency in healthy donors and comprise naïve and memory cells.

Authors:  Sylvain Meunier; Catherine Menier; Elodie Marcon; Sébastien Lacroix-Desmazes; Bernard Maillère
Journal:  Blood Adv       Date:  2017-09-25

2.  Factor VIII inhibitors: von Willebrand factor makes a difference in vitro and in vivo.

Authors:  Q Shi; E L Kuether; J A Schroeder; C L Perry; S A Fahs; J Cox Gill; R R Montgomery
Journal:  J Thromb Haemost       Date:  2012-11       Impact factor: 5.824

3.  Recombinant Factor VIII Measurement in a Hemophilia A Patient Undergoing Cardiopulmonary Bypass-Supported Cardiac Surgery.

Authors:  Jennifer Bezaire; Dorothy Thomson; Erick McNair
Journal:  J Extra Corpor Technol       Date:  2018-09

4.  FcRn Rescues Recombinant Factor VIII Fc Fusion Protein from a VWF Independent FVIII Clearance Pathway in Mouse Hepatocytes.

Authors:  Arjan van der Flier; Zhan Liu; Siyuan Tan; Kai Chen; Douglas Drager; Tongyao Liu; Susannah Patarroyo-White; Haiyan Jiang; David R Light
Journal:  PLoS One       Date:  2015-04-23       Impact factor: 3.240

5.  Complementary Sets of Autoantibodies Induced by SARS-CoV-2, Adenovirus and Bacterial Antigens Cross-React with Human Blood Protein Antigens in COVID-19 Coagulopathies.

Authors:  Robert Root-Bernstein; Jack Huber; Alison Ziehl
Journal:  Int J Mol Sci       Date:  2022-09-29       Impact factor: 6.208

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.